Lilly is treating in vivo CAR-T as a platform race, not a product race
$7B for Kelonia, two months after Orna, and a signal that Big Pharma is now paying for the next CAR-T manufacturing model.
I was in China for the past two weeks for meetings and ChinaBio, and being on the ground there is a useful reminder that advanced therapies can no longer be read through a single geography. The science, capital, and platform logic are all moving cross-border, fast. That is part of why Lilly’s latest move in in vivo CAR-T feels so important.
Last week, I wrote that in vivo CAR-T is starting to look clinically real. This week, Lilly made it look strategically real.
On April 20, 2026, Lilly announced that it will acquire Kelonia Therapeutics for up to $7.0 billion, including $3.25 billion upfront and additional clinical, regulatory, and commercial milestone payments.[1] Kelonia’s lead program, KLN-1010, is a Phase 1 in vivo anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma.[1]
What makes this deal interesting is not only the size. It is the timing.
Two months earlier, Lilly also agreed to acquire Orna Therapeutics for up to $2.4 billion, adding a circular RNA and LNP-based in vivo CAR-T platform initially aimed at B cell-driven autoimmune diseases.[2]
So in less than one quarter, Lilly has committed up to $9.4 billion across two different in vivo cell engineering platforms.[1][2]
Of course, turns out this is more than a casual business development.
Key readouts
Lilly agreed to acquire Kelonia for up to $7.0B, including $3.25B upfront.[1]
Kelonia’s lead asset, KLN-1010, is a Phase 1 in vivo anti-BCMA CAR-T program in relapsed or refractory multiple myeloma.[1]
Kelonia reported early ASH 2025 data from the first four patients showing 100% MRD-negative responses, with no grade 3 or higher CRS and no ICANS reported in that early dataset.[5]
Lilly had already agreed to acquire Orna for up to $2.4B in February 2026.[2]
Kelonia and Orna give Lilly two different routes into in vivo cell engineering: lentiviral iGPS and circular RNA/LNP.[1][2]
This follows a broader Big Pharma acquisition wave around in vivo CAR-T and in vivo cell engineering, including AbbVie/Capstan, BMS/Orbital, Kite/Interius, and AstraZeneca/EsoBiotec.[6][7][8][9]
Why this matters
This is not just a $7B oncology deal.
It is a sign that Big Pharma is trying to own the next manufacturing model for cell therapy.
If conventional CAR-T is built around leukapheresis, ex vivo engineering, expansion, release testing, and vein-to-vein logistics, in vivo CAR-T shifts the battlefield toward delivery, tropism, vector control, immune kinetics, and platform repeatability.
The bigger strategic question:
Whether the field can move part of CAR-T manufacturing from the factory into the patient.
What exactly did Lilly buy?
At the asset level, Lilly bought KLN-1010, Kelonia’s investigational one-time intravenous in vivo gene therapy that generates anti-BCMA CAR-T cells inside the patient.[1]
At the platform level, Lilly bought something more important: Kelonia’s iGPS platform, or in vivo Gene Placement System.[1]
Kelonia describes iGPS as a system using specially engineered lentiviral-based particles designed to efficiently and selectively enter T cells inside the body.[1] The goal is to let the patient generate CAR-T cells after a single intravenous administration, without the full conventional workflow of extracting, engineering, expanding, and reinfusing patient cells.[1]
That distinction matters. Lilly is not just buying a myeloma asset.
It is buying a delivery and integration platform that could potentially extend beyond BCMA, beyond multiple myeloma, and possibly beyond hematologic malignancy if the biology can be controlled.
This is why the deal is interesting.
A single-product acquisition would be easier to understand. A platform acquisition at this price says Lilly is trying to buy optionality in the architecture of future cell therapy.
Why Kelonia was already strategically visible
Kelonia was not an invisible platform before Lilly arrived.
In February 2024, Astellas and Kelonia entered a research and license agreement to develop in vivo CAR-T cell therapies for up to two immuno-oncology programs.[3] The deal included $40 million upfront for the first program, a possible additional $35 million if Astellas exercised the second-program option, and potential milestone and contingency payments approaching $800 million.[3]
In November 2025, Kelonia also announced a strategic collaboration with Johnson & Johnson to advance next-generation in vivo CAR-T therapies using the iGPS platform.[4]
So Lilly is not buying a random early platform.
It is acquiring a company that had already been validated, at least strategically, by multiple large biopharma players.
That does not mean the platform is de-risked.
That said, it does mean Kelonia had become visible in the exact place where value is forming: the intersection of in vivo delivery, CAR-T generation, and platform extensibility.
What did the early KLN-1010 data show?
Kelonia’s first-in-human data, presented at ASH 2025, came from the first four patients in the Phase 1 inMMyCAR study.[5]
The reported signal was striking:
100% MRD-negative response rate across four patients[5]
responses maintained through three months in the two patients with the longest follow-up[5]
potent CAR-T expansion from a single off-the-shelf infusion without chemotherapy[5]
no grade 3 or higher CRS reported[5]
no ICANS reported[5]
no delayed neurotoxicity reported[5]
That is why the asset drew attention.
Four patients is not a registrational dataset. It is an early clinical signal. It can support excitement, but not certainty.
So my read is this:
The KLN-1010 data are strong enough to make the platform commercially interesting, but still early enough that Lilly is not buying proof. Lilly is buying a high-conviction option on a modality shift.
Why buy both Kelonia and Orna?
This is the most interesting part of the Lilly strategy.
Kelonia and Orna are not the same bet.
Kelonia gives Lilly a lentiviral-based in vivo gene delivery and integration platform, with KLN-1010 leading in BCMA multiple myeloma.[1]
Orna gives Lilly an engineered circular RNA and LNP platform, with its lead program ORN-252, a CD19-targeting in vivo CAR-T therapy designed for B cell-driven autoimmune diseases.[2]
In simple terms:
Kelonia = lentiviral in vivo CAR-T, oncology-facing, integrating delivery logic.
Orna = circular RNA/LNP in vivo CAR-T, autoimmune-facing, RNA delivery logic.
That dual-track strategy is important.
Lilly is not simply asking, “Which single in vivo CAR-T asset should we own?”
It appears to be asking a bigger question:
Which delivery architecture will win the next phase of cell therapy?
That is why buying both companies makes strategic sense. The field is still early. The winning technology stack is not obvious. Lilly is buying multiple shots on goal across delivery modality, disease area, and platform biology.
Why is Big Pharma moving so fast?
Lilly is not alone.
Since 2025, several major pharma companies have moved into in vivo CAR-T or adjacent in vivo cell engineering:
AstraZeneca agreed to acquire EsoBiotec for up to $1B.[9]
AbbVie completed its acquisition of Capstan Therapeutics, adding an in vivo tLNP anti-CD19 CAR-T candidate for B cell-mediated autoimmune diseases.[6]
Kite, a Gilead company, agreed to acquire Interius BioTherapeutics for $350M.[8]
BMS agreed to acquire Orbital Therapeutics for $1.5B, adding an RNA platform and an in vivo CAR-T candidate in autoimmune disease.[7]
Lilly then acquired Orna and Kelonia, committing up to $9.4B across the two deals.[1][2]
This is not yet proof that in vivo CAR-T will win, even though it is clear evidence that Big Pharma is no longer treating the category as a fringe idea.
The reason is straightforward.
Conventional ex vivo CAR-T has already proven that engineered immune cells can deliver transformative clinical outcomes. But the model is operationally heavy: individualized manufacturing, complex logistics, variable patient material, lymphodepletion, capacity constraints, and high treatment burden.
In vivo CAR-T tries to attack the same therapeutic ambition with a different operating model.
Instead of taking cells out, engineering them in a facility, and putting them back in, the goal is to deliver the genetic instruction directly into the body and generate the therapeutic cells in vivo.
That is the moonshot, as well as the risk.
What still has to be proven?
The biggest mistake would be to read these deal values as if the modality is already solved. It is not.
Several questions remain open.
First, delivery specificity. Can the system reliably engineer the right cell type, in the right tissue context, at the right dose, without creating unacceptable off-target risk?
Second, control. Conventional cell therapy already has challenges around expansion, persistence, toxicity, and heterogeneity. In vivo approaches add another layer: the manufacturing process is now partly happening inside the patient. That makes control biology even more important.
Third, safety. CRS, neurotoxicity, cytopenias, vector behavior, immunogenicity, and integration-related questions all remain critical depending on the platform architecture.
Fourth, durability. Early responses are promising, but the field needs longer follow-up, broader patient numbers, and clearer evidence that in vivo-generated CAR-T cells can deliver durable benefit.
Fifth, scalability. In vivo CAR-T could reduce cell processing complexity, but it does not eliminate manufacturing. It shifts manufacturing pressure toward vectors, particles, LNPs, quality control, release criteria, and delivery reproducibility.
So the better framing is not:
in vivo CAR-T will replace ex vivo CAR-T.
The better framing is:
in vivo CAR-T is now being tested as a serious alternative manufacturing model for cell therapy.
That is a very different claim.
And it is the right one.
My read
The Lilly-Kelonia deal is important because it puts a number on what strategic buyers are willing to pay for in vivo CAR-T optionality.
Not just clinical signal.
Not just BCMA.
Not just a myeloma asset.
But the possibility of owning a platform that changes the manufacturing logic of cell therapy.
Ex vivo CAR-T is not going away. The clinical impact is too real, and the infrastructure is already too embedded. On the other hand, the limitations are also obvious. Manufacturing complexity, cost, access, and logistics have always been part of the strategic pain.
In vivo CAR-T is trying to answer that pain at the platform level.
That is why Big Pharma is moving.
And that is why Lilly’s two acquisitions matter.
Orna gives Lilly one route.
Kelonia gives Lilly another.
Together, they suggest that Lilly is no longer watching the in vivo CAR-T race from the outside. It is trying to build a position across the technology stack before the winner is obvious.
That is probably the right move.
In platform markets, waiting for perfect proof often means paying too late.
What should global CGT readers take away?
The takeaway is not that in vivo CAR-T is solved.
The takeaway is that in vivo CAR-T has entered the strategic acquisition phase.
That matters for biotech founders, CDMOs, investors, and anyone working around advanced therapy infrastructure.
For founders, the signal is clear: delivery architecture is becoming strategic value.
For investors, the signal is clear: early clinical data can create enormous platform leverage when it sits on top of a repeatable modality.
For CDMOs and manufacturing groups, the signal is clear: the manufacturing burden may shift, but it will not disappear. Vector, RNA, LNP, analytics, release testing, and process control may become even more important.
For global CGT readers, the bigger point is this:
The next CAR-T race may not be decided only by the best CAR design.
It may be decided by who controls the best way to generate the cell therapy in the first place.
That is why the Lilly-Kelonia deal matters.
It is not just another oncology acquisition.
It is one of the clearest signs yet that in vivo CAR-T is becoming a platform race.
Sources
[1] Eli Lilly and Company, “Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies,” April 20, 2026.
[2] Eli Lilly and Company, “Lilly to acquire Orna Therapeutics to advance cell therapies,” February 9, 2026.
[3] Astellas Pharma, “Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics,” February 16, 2024.
[4] Kelonia Therapeutics, “Kelonia Therapeutics Enters into Strategic Collaboration with Johnson & Johnson to Advance in vivo CAR-T Therapies,” November 5, 2025.
[5] Kelonia Therapeutics, “Kelonia Therapeutics Presents First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting,” December 9, 2025.
[6] AbbVie, “AbbVie Completes Acquisition of Capstan Therapeutics,” August 19, 2025.
[7] Bristol Myers Squibb, “Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics,” October 10, 2025.
[8] Interius BioTherapeutics, “Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform,” August 21, 2025.
[9] AstraZeneca, “Acquisition of EsoBiotec completed,” May 20, 2025.